Please select the eligibility criteria that correspond to the clinical trial below.
Title: Glove-loaded Foley's Catheter Tamponade to Reducing Blood Loss During Cesarean Delivery for Complete Placenta Previa: a Randomized Controlled Trial
Brief Summary: Objective: To investigate the effect of A glove-loaded Foley's catheter tamponade versus stepwise uterine devascularization on blood loss during cesarean section (CS) in patients with complete placenta previa.


Options:
A: Inclusion Criteria:

* All pregnant females aged 18 years or more, candidate for normal vaginal delivery during the period of the study will be included

Exclusion Criteria:

* Women presenting with pre-existing maternal hemorrhagic conditions such as factor 8 or 9 deficiency or Von Willebrand's disease or those who had assisted vaginal delivery
B: Inclusion Criteria:

* all pregnant women with a single-term fetus scheduled for elective CD for complete placenta previa

Exclusion Criteria:

* • Patients with the cardiac, hepatic, renal, or thromboembolic disease;

  * patients with the high possibility of morbid adherent placenta;
  * known coagulopathy, and
  * those presented with severe antepartum hemorrhage were excluded.
C: Inclusion Criteria:

* Patient undergoing caesarean sections landing up in atonic PPH during LSCS with failure of medical line of management:

  1. Full term pregnancy
  2. Didn't complete her family
  3. Elective caesarian section

Exclusion Criteria:

* 1.) PPH after vaginal delivery 2.) Secondary PPH 3.) PPH due to causes other than atonicity 4.) Antepartum hemorrhage cases 5.) Patients with bleeding tendency 6.) If any complication occurred during caesarian section (e.g. bladder injury, DIC)
D: Inclusion Criteria:

The trial will include women:

* aged 18 years or older,
* who have just had a vaginal delivery
* between 35 and 42 weeks of gestation
* with a PPH persisting 15 minutes after the injection of 5 UI or 10 IU of oxytocin by slow IV and uterine massage,
* and who provided informed written consent. If her condition does not allow her consent to be obtained immediately in ethically acceptable conditions, it may be obtained from her healthcare agent, or if there is none, from a family member, if present. In case where neither a healthcare agent nor a family member is present on the day of inclusion, the patient can nonetheless be included. She will be informed secondarily, and her consent will be requested for the potential continuation of the research and use of her data
* Patient beneficiary or affiliated to a health insurance

Exclusion Criteria:

The trial will not include women:

* who have just had a cesarean delivery
* with a contraindication to Sulprostone
* with clinical chorioamnionitis or an in utero fetal death
* or a medically-indicated termination of pregnancy
* with PPH secondary to cervicovaginal lacerations without any uterine hemorrhage, uterine rupture, or placenta accreta
* with arterial bleeding requiring embolization
* with a purulent infection of the cervix, vagina or uterus
* with symptoms indicating a hysterectomy
* with cervical cancer
* with a uterine malformation
* or who refuses to sign the informed consent.

Answer: B